GLP-1 (7-37)

Bezeichnung:GLP-1 (7-37)

CAS-Nr106612-94-6

Englisch Name:GLP-1 (7-37)

CBNumberCB1445727

SummenformelC151H228N40O47

Molgewicht3355.67

MOL-Datei106612-94-6.mol

GLP-1 (7-37) physikalisch-chemischer Eigenschaften

Dichte	1.48±0.1 g/cm3(Predicted)
storage temp.	−20°C
Löslichkeit	Water:30.0(Max Conc. mg/mL);8.34(Max Conc. mM)
Aggregatzustand	Lyophilized powder
Farbe	White to off-white
Wasserlöslichkeit	Soluble in water at 2mg/ml
Sequenz	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH
CAS Datenbank	106612-94-6

Sicherheit

S-Sätze:	22-24/25
WGK Germany	3

GLP-1 (7-37) Chemische Eigenschaften,Einsatz,Produktion Methoden

S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
Beschreibung
GLP-1 (7-37) is an endogenous truncated form of GLP-1 that arises from proglucagon processing in intestinal endocrine L cells, GLP-1 (7-37) acts as a GLP-1 receptor agonist and is an insulinotropic hormone that augments glucose induced insulin secretion. GLP-1 (7-37) and derivatives GLP-1 (9-37) and GLP-1 (28-37) can reduce plaque inflammation and increase phenotypic characteristics of plaque stability in a murine model of atherosclerosis.
Verwenden
Glucagon-Like Peptide 1 Fragment 7-37 human has been used:
- as a positive control for insulin secretion of pancreatic islets
- to test its effect on insulin response in horse islets
- in combination with mesenchymal stem cells (MSCs) test its protective effects in myocardial infarction
Allgemeine Beschreibung
Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) is an amino-truncated form of GLP-1.
Biochem/physiol Actions
Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality.
in vitro
In vitro, truncated glucagon-like peptides [GLP-1(7-36)-amide and GLP-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of GLP-1(7-37) has been demonstrated acutely with high concentrations.
in vivo
GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats. Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM.
Lager
Store at -20°C

GLP-1 (7-37) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy